These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

402 related items for PubMed ID: 19131179

  • 1. Hypofractionated intensity-modulated radiotherapy for carcinoma of the prostate: analysis of toxicity.
    Coote JH, Wylie JP, Cowan RA, Logue JP, Swindell R, Livsey JE.
    Int J Radiat Oncol Biol Phys; 2009 Jul 15; 74(4):1121-7. PubMed ID: 19131179
    [Abstract] [Full Text] [Related]

  • 2. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.
    Lim TS, Cheung PC, Loblaw DA, Morton G, Sixel KE, Pang G, Basran P, Zhang L, Tirona R, Szumacher E, Danjoux C, Choo R, Thomas G.
    Int J Radiat Oncol Biol Phys; 2008 Sep 01; 72(1):85-92. PubMed ID: 18355982
    [Abstract] [Full Text] [Related]

  • 3. Hypofractionated intensity-modulated radiotherapy (70 gy at 2.5 Gy per fraction) for localized prostate cancer: long-term outcomes.
    Kupelian PA, Thakkar VV, Khuntia D, Reddy CA, Klein EA, Mahadevan A.
    Int J Radiat Oncol Biol Phys; 2005 Dec 01; 63(5):1463-8. PubMed ID: 16169683
    [Abstract] [Full Text] [Related]

  • 4. Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV.
    Michalski JM, Winter K, Purdy JA, Perez CA, Ryu JK, Parliament MB, Valicenti RK, Roach M, Sandler HM, Markoe AM, Cox JD.
    Int J Radiat Oncol Biol Phys; 2004 Mar 01; 58(3):735-42. PubMed ID: 14967428
    [Abstract] [Full Text] [Related]

  • 5. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D, Martinez A, Yan D, Lockman D, Wallace M, Gustafson G, Chen P, Vicini F, Wong J.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):400-8. PubMed ID: 15667959
    [Abstract] [Full Text] [Related]

  • 6. Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V.
    Michalski JM, Winter K, Purdy JA, Parliament M, Wong H, Perez CA, Roach M, Bosch W, Cox JD.
    Int J Radiat Oncol Biol Phys; 2005 Jul 01; 62(3):706-13. PubMed ID: 15936549
    [Abstract] [Full Text] [Related]

  • 7. Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma.
    Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, Gospodarowicz M, McLean M, Ménard C, Milosevic M, Warde P, Catton C.
    Int J Radiat Oncol Biol Phys; 2007 Nov 15; 69(4):1084-9. PubMed ID: 17606331
    [Abstract] [Full Text] [Related]

  • 8. Role of principal component analysis in predicting toxicity in prostate cancer patients treated with hypofractionated intensity-modulated radiation therapy.
    Vesprini D, Sia M, Lockwood G, Moseley D, Rosewall T, Bayley A, Bristow R, Chung P, Ménard C, Milosevic M, Warde P, Catton C.
    Int J Radiat Oncol Biol Phys; 2011 Nov 15; 81(4):e415-21. PubMed ID: 21477939
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Toxicity assessment of pelvic intensity-modulated radiotherapy with hypofractionated simultaneous integrated boost to prostate for intermediate- and high-risk prostate cancer.
    McCammon R, Rusthoven KE, Kavanagh B, Newell S, Newman F, Raben D.
    Int J Radiat Oncol Biol Phys; 2009 Oct 01; 75(2):413-20. PubMed ID: 19362783
    [Abstract] [Full Text] [Related]

  • 12. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T, Katoh H, Noda SE, Ito K, Yamamoto T, Kashiwagi B, Nakano T.
    Int J Radiat Oncol Biol Phys; 2005 Oct 01; 63(2):472-8. PubMed ID: 16168839
    [Abstract] [Full Text] [Related]

  • 13. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.
    Wong GW, Palazzi-Churas KL, Jarrard DF, Paolone DR, Graf AK, Hedican SP, Wegenke JD, Ritter MA.
    Int J Radiat Oncol Biol Phys; 2008 Feb 01; 70(2):449-55. PubMed ID: 17869014
    [Abstract] [Full Text] [Related]

  • 14. Intensity-modulated radiotherapy as primary therapy for prostate cancer: report on acute toxicity after dose escalation with simultaneous integrated boost to intraprostatic lesion.
    Fonteyne V, Villeirs G, Speleers B, De Neve W, De Wagter C, Lumen N, De Meerleer G.
    Int J Radiat Oncol Biol Phys; 2008 Nov 01; 72(3):799-807. PubMed ID: 18407430
    [Abstract] [Full Text] [Related]

  • 15. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes.
    Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S, Amols H.
    Int J Radiat Oncol Biol Phys; 2008 Jun 01; 71(2):330-7. PubMed ID: 18164858
    [Abstract] [Full Text] [Related]

  • 16. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial.
    King CR, Brooks JD, Gill H, Pawlicki T, Cotrutz C, Presti JC.
    Int J Radiat Oncol Biol Phys; 2009 Mar 15; 73(4):1043-8. PubMed ID: 18755555
    [Abstract] [Full Text] [Related]

  • 17. Analysis of toxicity in patients with high risk prostate cancer treated with intensity-modulated pelvic radiation therapy and simultaneous integrated dose escalation to prostate area.
    Arcangeli S, Saracino B, Petrongari MG, Gomellini S, Marzi S, Landoni V, Gallucci M, Sperduti I, Arcangeli G.
    Radiother Oncol; 2007 Aug 15; 84(2):148-55. PubMed ID: 17692416
    [Abstract] [Full Text] [Related]

  • 18. High-dose intensity-modulated radiotherapy as primary therapy for prostate cancer: report on dosimetry aspects and acute toxicity in the Indian scenario.
    De S, Kannan V, Deshpande S, Anand V, Ghadi Y.
    J Cancer Res Ther; 2010 Aug 15; 6(1):58-64. PubMed ID: 20479549
    [Abstract] [Full Text] [Related]

  • 19. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer.
    Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI.
    Int J Radiat Oncol Biol Phys; 2008 Mar 15; 70(4):1124-9. PubMed ID: 18313526
    [Abstract] [Full Text] [Related]

  • 20. Hypofractionated radiotherapy for favorable risk prostate cancer.
    Rene N, Faria S, Cury F, David M, Duclos M, Shenouda G, Souhami L.
    Int J Radiat Oncol Biol Phys; 2010 Jul 01; 77(3):805-10. PubMed ID: 20510194
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.